

# Transforming Breast Health Through Imaging Intelligence

## Snapshot

The first FDA-cleared platform combining anatomic and functional breast imaging with quantitative transmission ultrasound, AI, and biomarkers for safer, earlier, more accurate care.

**Disruptive Innovation:** Using technology (software, machine learning, and smart physics) to improve medical imaging

**FDA Cleared:** Indicated for breast imaging, for patients 18 years of age and older

**Scalable Vision:** Bridging clinical and consumer markets for whole-body imaging

**Strong Support:** Backed by ~\$18M in NIH funding to develop next-gen women's imaging solutions

## The Problem

### Challenges of Current Standard of Care

- **Low Compliance:** 25% of women avoid regular screening due to discomfort and accessibility
- **High Recall Rates:** ~15% callback rate; 98% of recalls are avoidable
- **Unnecessary Biopsies:** Over 80% of biopsies from callbacks are benign
- **Limited in Dense Breasts:** Mammography can miss ~35–52% of cancers in dense tissue






## Our Solution

### Quantitative Transmission Imaging (QTI)

A new category of true 3D, high resolution, quantitative ultrasound-based imaging

- **3D Volumetric Imaging:** Uses CT-like configuration with ultrasound to map speed-of-sound across tissue volume
- **MRI-like Resolution:** Achieved without contrast agents and without the enclosed environment associated with MRI
- **Clear, Overlap-Free Imaging:** Provides more comprehensive tissue information than conventional mammography
- **Consistent & Standardized Imaging:** Overcomes operator dependence and lack of standardization seen with handheld ultrasound (HHUS)
- **Safe & Comfortable:** Pain free, safe, on average 10–12 min scan per breast

## QTI vs. Traditional Breast Imaging Modalities

	 <b>QT Scan</b> <b>Ultrasound</b>	 <b>HHUS</b> <b>Ultrasound</b>	 <b>CE-MRI</b> <b>Magnetic Resonance</b>	 <b>XRM/DBT</b> <b>X-Ray</b>	 <b>Breast CT</b> <b>X-Ray</b>
Underlying Technology	Ultrasound	Ultrasound	Magnetic Resonance	X-Ray	X-Ray
Image Quality	●	◐	●	◐	●
Safety <sup>1</sup>	●	●	◐	◐	◐
Cost Efficiency	●	◐	◐	◐	◐
Patient Experience	●	◐	◐	○	●

### The QTI Imaging Advantage

#### ...OVER HHUS

- Superior image quality
- Not operator dependent
- Quantifiable/repeatable

#### ...OVER MRI

- High resolution and contrast-to-noise ratio
- No injection needed
- Lower equipment cost
- No special facility or shielding requirements

#### ...OVER XRM/DBT

- Improved image quality
- Safer (no radiation), allowing for more frequent imaging
- Greater specificity
- No special facility requirements
- Quantifiable/repeatable

#### ...OVER BREAST CT

- No radiation – breast CT radiation is significantly higher than screening mammography
- No contrast needed (compared to contrast enhanced CT)

<sup>1</sup>) No radiation exposure or injections necessary <https://www.bcrf.org/about-breast-cancer/breast-ultrasound/>  
[https://pmc.ncbi.nlm.nih.gov/articles/PMC10183872/?utm\\_source=chatgpt.com](https://pmc.ncbi.nlm.nih.gov/articles/PMC10183872/?utm_source=chatgpt.com)  
[https://winshipcancer.emory.edu/cancer-types-and-treatments/breast-cancer/screening.php?utm\\_source=chatgpt.com](https://winshipcancer.emory.edu/cancer-types-and-treatments/breast-cancer/screening.php?utm_source=chatgpt.com)  
<https://www.koninghealth.com/about-koning/frequently-asked-questions>

## Platform Pillars Overview

- Non-ionizing, high-resolution, 3D imaging scanner
- Image reconstruction SW to generate exceptional image quality
- AI-powered lesion classification
- Tissue biomarkers from speed-of-sound maps
- Cloud-based image analytics & reporting

## Proven Technology with Commercial Momentum

### Financial Highlights (Q1 2025):

- \$3.7M revenue from eight scanners shipped (50% gross margin); two additional scanners shipped in July
- \$0.7M PIPE investments funded by QTI BOD & Chairman of the Israel Cancer Association
- Announced newest image reconstruction software update release, version 4.4.0, and launched latest QTviewer™, version 2.8
- Appointed Elaine Iuanow, MD, as Chief Medical Officer
- Contracted sales of 100 scanners to be sold in 2025/26 for \$18M and \$27 in revenue, respectively

## Next Steps for Growth

- Drive sales and manufacturing expansion
- Support approvals for specific reimbursement codes
- Conduct clinical studies to support hospital adoption
- Add biopsy apparatus to the QT Scanner
- Build the QTI Cloud Platform to provide subscribers with access to a large and growing portfolio of AI-driven tools



## Clinical Use Cases

- Safe breast imaging option for patients 18 years of age or older
- Imaging option for patients unable to tolerate MRI (e.g., claustrophobia and contrast allergies)
- Supplemental imaging for women with dense breasts
- Adjunct follow-up for inconclusive or suspicious mammogram findings
- Ongoing monitoring of benign lesions (e.g., cysts, fibroadenomas) without radiation exposure
- Ongoing monitoring of lesion doubling time to assess growth dynamics

## Investment Highlights

- True 3D, Quantitative, High-Resolution Industry-Transforming Imaging Technology Platform Recognized by Industry Incumbents
- High-Value Entry in \$5B+ Breast Imaging Market, augmented by Scalable Path to \$22B+ Adjacent Applications<sup>1</sup>
- Strategic Canon Partnerships: Distribution via NXC Imaging + Scalable Manufacturing with Canon Medical Systems
- Strong Commercial Momentum with \$45M in Contracted 2025–26 Revenue
- Higher Specificity and Improved Non-Cancer Recall Rates Compared to Traditional Mammogram

<sup>1</sup>) Coherent Market Insights

DISCLAIMER: This information is published solely for informational purposes, does not purport to be all-inclusive, and is not to be construed as a solicitation or an offer to sell any security. The summary may include "forward-looking statements" with the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act of 1934 and are intended to be covered by the safe harbor provisions for forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties as described in our filings with the SEC. This information is supplied from sources we believe to be reliable, but we cannot guarantee accuracy. This document has been furnished to you solely for your information. Any company names or logos of other companies are the trademarks and/or intellectual property of those other companies, and their use is not intended to, and does not imply, a relationship with QTI or an endorsement or sponsorship by or of QTI.

## Contact

Stephen Kilmer, *Investor Relations*

**Direct:** (646) 274-3580 | **Email:** stephen.kilmer@qtimaging.com

[www.qtimaging.com](http://www.qtimaging.com)